Ticker

ArrowMark Colorado Holdings LLC increased its holdings in Stevanato Group S.p.A. (NYSE: STVN) by 6.7% in the undefined quarter, according to its most recent filing with the SEC. The institutional investor owned 1,392,581 shares of the company's stock after buying an additional 86,971 shares during the quarter. ArrowMark Colorado Holdings LLC owned about

Shares of Stevanato Group S.p.A. (NYSE: STVN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have issued a buy recommendation and

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Virtual Healthcare Forum taking place on Tuesday, March 17 and Wednesday, March 18, 2026. The Company will present…

Stevanato Group is reiterated as a Buy, supported by strong Q4/FY25 results and robust long-term demand drivers. While the Engineering division continues to weigh on margins and reported less than €40m in Q4 sales, the pressure appears cyclical. With ~90% of capex directed toward HVS expansion, the segment has limited impact on the group's long-term fundamentals.

Stevanato Group (NYSE: STVN) executives said the company closed fiscal 2025 with "solid" results and entered 2026 with positive momentum, driven by continued strength in its Biopharmaceutical and Diagnostic Solutions (BDS) segment and accelerating demand for high-value products tied to GLP-1 therapies. Fiscal 2025 and Q4 performance led by high-value solutions Chairman and CEO Franco Stevanato